👩⚕️ Regulatory hurdles and defensive tactics from incumbents hinder the growth of biosimilars in the US market.
👨🔬 QTL technology enables optimized production for individual biosimilars, increasing consistency and process control.
💰 Up-front costs for biosimilars using QTL technology are lower compared to traditional manufacturing methods.
🚀 A strategic approach can make biosimilars an attractive investment opportunity with long-lasting returns.
Introduction:
The article discusses how biosimilars, which are generic equivalents of biological therapeutics, have the potential to improve global health by increasing access to key medicines at lower prices. However, biosimilar projects face challenges such as high development costs, a competitive marketplace, and high manufacturing costs. The article introduces QTL technology as a solution to these challenges, enabling the optimization of production strains for individual biosimilars and reducing up-front costs. The use of QTL technology can make biosimilars a more compelling investment opportunity and improve the manufacturing process for monoclonal antibodies and other glycoproteins.
- Biosimilars offer greater access to key medicines at lower prices, but face challenges in development and manufacturing.
- The US system has not been welcoming to biosimilars, with tactics used to protect the market for original reference molecules.
- The use of contract development and manufacturing organizations (CDMOs) for biosimilar manufacturing is costly and vulnerable to market competition.
- Using microbial systems for manufacturing biosimilars faces knowledge barriers and proprietary strains.
- QTL technology enables the optimization of production strains for individual biosimilars, reducing costs and improving the manufacturing process.
Conclusion:
QTL technology offers a solution to the challenges faced by biosimilar projects, enabling the production of biosimilars at lower costs and with improved quality. This technology has the potential to make biosimilars a more attractive investment opportunity and improve global access to key medicines. By selecting the right biosimilar projects, targeting regulatory-friendly countries, and tracking emerging technologies, biosimilar developers can overcome regulatory obstacles and stimulate investor interest.
